Cancer Prevention Overview (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (07/07/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of the Evidence

Added text about the impact of finasteride on the incidence of prostate cancer, including its impact on the incidences of clinically significant, clinically insignificant, and high-grade prostate cancer. Also added text to state that similar results and controversy surround the impact of dutasteride on the incidence of prostate cancer. Also revised text to state that the impact of either finasteride or dutasteride on prostate cancer mortality is uncertain.

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of the Evidence

Next section >
About This PDQ Summary